Printer Friendly

SCHERER ANNOUNCES ZYDIS PRODUCT LAUNCH IN ITALY

 SCHERER ANNOUNCES ZYDIS PRODUCT LAUNCH IN ITALY
 TROY, Mich., May 15 /PRNewswire/ -- R.P. Scherer Corporation


(NYSE: SHR) announced today that another product utilizing the ZYDIS(R) Fast Dissolving Dosage Form Technology has been launched in Europe. Wyeth Italy has commenced marketing a fast-dissolving formulation of lorazepam (Trade Mark - TAVOR EXPIDET) as a line extension to their TAVOR range of products. Lorazepam is one of the most widely used benzodiazepine anxiolytics in Italy.
 The patented ZYDIS(R) technology enables pharmaceutical products to be made in a form which dissolves instantaneously on the tongue and which does not require water to aid swallowing. It is particularly suitable for children and elderly people, as well as many patients who have problems swallowing traditional tablets and hard-shell capsules. The technology was invented by Wyeth and jointly developed with R.P. Scherer Limited in the U.K. Scherer now has a worldwide licensing agreement with Wyeth enabling Scherer to develop and supply fast- dissolving formulations for other pharmaceutical companies.
 R.P. Scherer Corporation, a leading international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(R), ZYDIS(R) and PULSINCAP(TM) technologies. The company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The company operates a global network of 15 facilities in 11 countries.
 TAVOR and EXPIDET are registered trademarks of American Home Products Corporation.
 ZYDIS(R), SCHERERSOL(R) and PULSINCAP(TM) are registered trademarks of R.P. Scherer Corporation.
 -0- 5/15/92
 /CONTACT: Alex Erdeljan of R.P. Scherer Corporation, 313-649-0900/
 (SHR) CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU:


KK -- DE010 -- 0678 05/15/92 10:59 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 15, 1992
Words:302
Previous Article:ROYCE LABORATORIES ANNOUNCES FIRST QUARTER RESULTS
Next Article:ANADARKO ANNOUNCES COALBED GAS DISCOVERY
Topics:


Related Articles
R.P. SCHERER TERMINATES ACQUISITION DISCUSSIONS
SCHERER AND CHESEBROUGH-POND'S JOINTLY DEVELOP A NEW SKIN MOISTURIZER CAPSULE
SCHERER ANNOUNCES LAUNCH OF ANOTHER PRODUCT UTILIZING ITS ZYDIS(R) TECHNOLOGY
DR. STEWART JOHNSON APPOINTED MEDICAL DIRECTOR OF SCHERER'S NEWLY FORMED ADVANCED THERAPEUTIC PRODUCTS GROUP
SCHERER ANNOUNCES LAUNCH OF ANOTHER PRODUCT UTILIZING ITS ZYDIS TECHNOLOGY
Whitehall-Robins Healthcare Introduces 'Child-Friendly' Quick Dissolve Tablets For Cold and Allergy Relief
Scherer Announces U.S. Marketing Clearance for the First Prescription Product Using Zydis(R) Technology
Elan and Scherer Announce License for Zydis Formulation
R.P. Scherer/Orion Announce Agreement to Study, Market New Delivery Form of Parkinson's Therapy.
R.P. Scherer Unit Named Supplier of the Year By Schering Laboratories.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters